CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 519 enrolled
Drug / intervention
Ingenol Mebutate (Perrigo) +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02385318
NCT02385318Phase 3Completed
CompareCT.gov

To Compare Safety and Efficacy of Perrigo's Drug Product Compared to an FDA Approved Drug Product in the Treatment of Actinic Keratosis

Padagis LLC·interventional·Posted Mar 11, 2015·Updated Nov 2, 2021

In Brief

A Phase 3 clinical trial evaluating Ingenol Mebutate (Perrigo), Ingenol Mebutate (Reference), and 1 other intervention for Actinic Keratosis. Completed, enrolled 519 participants.

Detailed Summary

The purpose of this study is to compare safety and efficacy of Perrigo's drug product compared to an FDA approved drug product in the treatment of actinic keratosis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsActinic Keratosis
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedMar 11, 2015
Enrollment StartFeb 1, 2015
Primary CompletionDec 1, 2015
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 11.3 years ago

Interventions

Ingenol Mebutate (Perrigo)drug

Ingenol Mebutate (Reference)drug

Placebo geldrug